Amedisys sale to UnitedHealth unlikely to be done until at least end of November

UnitedHealth’s (UNH) planned purchase of Amedisys (NASDAQ:AMED) is unlikely to be completed until at least the end of November.

The Oregon Health Authority, which is a regulator that is reviewing the purchase of the home-health care provider, disclosed earlier this week that it expects to complete its review of the deal by the end of November, according to a posting on the regulator’s website.

The November date may be disappointing to some M&A investors who expected the deal may close sooner. The disclosure comes after UnitedHealth (UNH) in late June announced an agreement with VitalCaring Group to sell some of the two companies’ healthcare centers. The divestiture is being done to appease Department of Justice antitrust concerns over the more than $3B deal.

Amedisys (UNH) said in the 8-K filing in late June that it expected the deal to be completed in the second half of this year.

Amedisys (AMED), which agreed to a $101 a share sale to UnitedHealth in late June of last year, is waiting for the DOJ to sign off on the deal for the home-health care provider. Amedisys announced in August 2023 that it received a request from the DOJ for more information regarding its planned sale to UnitedHealth (UNH).

UnitedHealth (UNH) is scheduled to report Q3 results on Oct. 15. Amedisys (AMED) ticked lower by 0.3% on Wednesday.